Solid Biosciences Inc (SLDB) FinancialsSLDBSolid Biosciences Inc

Evaluating the bottom line, Solid Biosciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -65.50%, provide a clear picture of how effectively SLDB converts its operational activities into shareholder value.

In the context of the broader market, SLDB competes directly with industry leaders such as ATTO and EPRX. With a market capitalization of $686.24M, it holds a leading position in the sector. When comparing efficiency, SLDB's gross margin of N/A stands against ATTO's 100.00% and EPRX's N/A. Such benchmarking helps identify whether Solid Biosciences Inc is trading at a premium or discount relative to its financial performance.

The company has a current ratio of 13.82, indicating strong liquidity, and a low debt to equity ratio of 0.00%, suggesting minimal financial risk from debt. However, it has reported consistent net losses, with a net income of -56.7 million in Q1 2026.